Participating Member Institution in NABTC

NABTC 参与会员机构

• 批准号: 6738685
• 负责人: LISA M DEANGELIS
• 金额: $ 15.33万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-18 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6738685
• 关键词: adult human (21+); blood banks; brain neoplasms; clinical research; clinical trial phase I; clinical trial phase II; cooperative study; disease /disorder model; drug delivery systems; drug design /synthesis /production; drug discovery /isolation; drug screening /evaluation; glioma; human subject; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer relapse /recurrence; patient oriented research; pharmacokinetics; tissue resource /registry

DESCRIPTION (provided by applicant): Memorial Sloan-Kettering Cancer Center (MSKCC) will participate in the clinical trials of the North American Brain Tumor Consortium (NABTC). The University of California San Francisco (UCSF) will be the lead institution and Dr. Michael Prados will be the group leader for the NABTC. Member institutions of the NABTC will include UCSF, the University of Wisconsin, the University of Pittsburgh, MD Anderson Cancer Center, Dana Farber Cancer Center, University of California, Los Angeles and the Neuro-oncology Branch of the National Institutes of Health in addition to MSKCC. The pharmacokinetic center will be located at the University of Texas, San Antonio. The focus of this grant is to continue to initiate and conduct investigational Phase I/II trials in adult patients with primary brain tumors with a particular emphasis on malignant glioma. Patients at MSKCC will be evaluated and treated by a multidisciplinary team composed of neuro-oncologists, neurosurgeons, radiation oncologists, neuropathologists, neuroradiologists and clinical research nurses; data will be monitored, evaluated and collated by dedicated data managers. MSKCC has state-of-the-art neuroimaging capabilities and dedicated neuroradiologists to develop and participate in imaging projects coincident with planned clinical studies. MSKCC has an active tumor bank and brain tumor tissue obtained from patients at the time of surgery is collected and stored in a tissue bank for ongoing and future laboratory studies; tumor tissue from patients enrolled in NABTC trials will also provide an opportunity for clinical and laboratory correlations specific to the investigational agent under study. The NABTC is multi-institutional to facilitate rapid patient accrual into Phase I/II trials of investigational agents for brain tumor treatment, to share brain tumor specimens among member institutions and to cooperate in developing concurrent laboratory and translational research programs that complement the active clinical trials being conducted within the consortium. MSKCC and the NABTC will be linked to the ongoing interests, needs and support of the Cancer Therapy Evaluation Program (CTEP) and the Radiation Research Program (RRP) of the Division of Cancer Treatment at the National Cancer Institute. The overriding goal of this program is to identify and develop improved therapy for patients with primary brain tumors, particularly those with malignant gliomas, with the purpose of extending the duration and quality of survival.

描述（由申请人提供）：纪念斯隆 - 凯特林癌症中心（MSKCC）将参加北美脑肿瘤财团（NABTC）的临床试验。加利福尼亚大学旧金山大学（UCSF）将是主要机构，迈克尔·普拉多斯（Michael Prados）博士将成为NABTC的小组负责人。 NABTC的会员机构将包括UCSF，威斯康星大学，匹兹堡大学，医学博士安德森癌症中心，达纳·法伯癌症中心，加利福尼亚大学，洛杉矶大学和国立卫生研究院的神经肿瘤学分支。药代动力学中心将位于得克萨斯大学圣安东尼奥分校。该赠款的重点是继续在原发性脑肿瘤的成年患者中启动和进行研究期I/II阶段试验，并特别强调恶性神经胶质瘤。 MSKCC的患者将由由神经肿瘤学家，神经外科医生，放射性肿瘤学家，神经病理学家，神经放射学家和临床研究护士组成的多学科团队进行评估和治疗；专门的数据经理将监视，评估和整理数据。 MSKCC具有最先进的神经影像学能力，并且具有专门的神经放射学家来发展和参与与计划的临床研究相吻合的成像项目。 MSKCC在手术时具有从患者中获得的活跃肿瘤库，并在组织库中收集了从患者中获得的脑肿瘤组织，以进行正在进行的和未来的实验室研究。参加NABTC试验的患者的肿瘤组织还将为研究药物特定的临床和实验室相关性提供机会。 NABTC是多机构的，可以促进患者的快速患者参与研究剂的I/II阶段试验，以进行脑肿瘤治疗的I/II阶段试验，以在成员机构之间共享脑肿瘤标本，并在开发并发的实验室和转化研究计划中合作，以补充该联盟内进行的主动临床试验。 MSKCC和NABTC将与国家癌症研究所的癌症治疗部门的癌症治疗评估计划（CTEP）（CTEP）（CTEP）（RRP）的持续利益，需求和支持有关。该计划的重要目标是确定和开发针对原发性脑肿瘤（尤其是恶性神经胶质瘤患者）患者的改进治疗，目的是延长生存的持续时间和质量。